Zobrazeno 1 - 10
of 869
pro vyhledávání: '"Jack A. Roth"'
Autor:
Franziska Haderk, Yu-Ting Chou, Lauren Cech, Celia Fernández-Méndez, Johnny Yu, Victor Olivas, Ismail M. Meraz, Dora Barbosa Rabago, D. Lucas Kerr, Carlos Gomez, David V. Allegakoen, Juan Guan, Khyati N. Shah, Kari A. Herrington, Oghenekevwe M. Gbenedio, Shigeki Nanjo, Mourad Majidi, Whitney Tamaki, Yashar K. Pourmoghadam, Julia K. Rotow, Caroline E. McCoach, Jonathan W. Riess, J. Silvio Gutkind, Tracy T. Tang, Leonard Post, Bo Huang, Pilar Santisteban, Hani Goodarzi, Sourav Bandyopadhyay, Calvin J. Kuo, Jeroen P. Roose, Wei Wu, Collin M. Blakely, Jack A. Roth, Trever G. Bivona
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-19 (2024)
Abstract Targeted therapy is effective in many tumor types including lung cancer, the leading cause of cancer mortality. Paradigm defining examples are targeted therapies directed against non-small cell lung cancer (NSCLC) subtypes with oncogenic alt
Externí odkaz:
https://doaj.org/article/be0a7eca3725431ab19bfe58739629b9
Autor:
Ismail M. Meraz, Mourad Majidi, Bingliang Fang, Feng Meng, Lihui Gao, RuPing Shao, Renduo Song, Feng Li, Yonathan Lissanu, Huiqin Chen, Min Jin Ha, Qi Wang, Jing Wang, Elizabeth Shpall, Sung Yun Jung, Franziska Haderk, Philippe Gui, Jonathan Wesley Riess, Victor Olivas, Trever G. Bivona, Jack A. Roth
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-17 (2023)
Abstract Osimertinib sensitive and resistant NSCLC NCI-H1975 clones are used to model osimertinib acquired resistance in humanized and non-humanized mice and delineate potential resistance mechanisms. No new EGFR mutations or loss of the EGFR T790M m
Externí odkaz:
https://doaj.org/article/14668810c2ce4d07aa43ff0a81c3c865
Autor:
Nathaniel Deboever, Nicolas Zhou, Daniel J. McGrail, Katarzyna Tomczak, Jacqueline L. Oliva, Hope A. Feldman, Edwin Parra, Jianjun Zhang, Percy P. Lee, Mara B. Antonoff, Wayne L. Hofstetter, Reza J. Mehran, Ravi Rajaram, David C. Rice, Jack A. Roth, Stephen S. Swisher, Ara A. Vaporciyan, Mehmet Altan, Annikka Weissferdt, Anne S. Tsao, Cara L. Haymaker, Boris Sepesi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundMalignant pleural mesothelioma (MPM) is associated with poor prognosis despite advances in multimodal therapeutic strategies. While patients with resectable disease may benefit from added survival with oncologic resection, patient selection
Externí odkaz:
https://doaj.org/article/31d96bb81be04ff5b9ce89f4dbae9747
Autor:
Hope A. Feldman, MD, Nicolas Zhou, DO, Nathanial Deboever, MD, Wayne Hofstetter, MD, Reza Mehran, MD, Ravi Rajaram, MD, David Rice, MD, Jack A. Roth, MD, Boris Sepesi, MD, Stephen Swisher, MD, Ara Vaporciyan, MD, Garrett Walsh, MD, Myrna Godoy, MD, PhD, Chad Strange, MD, Mara B. Antonoff, MD
Publikováno v:
JTCVS Open, Vol 12, Iss , Pp 372-384 (2022)
Objectives: Neoadjuvant therapy has been theorized to increase complexity of non–small cell lung cancer resections; however, specific factors that contribute to intraoperative challenges after induction therapy have not been well described. We aime
Externí odkaz:
https://doaj.org/article/a7297ecb57e242b1aed710f1b7fb85f9
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Anticancer combination therapy has been developed to increase efficacy by enhancing synergy. Patient-derived xenografts (PDXs) have emerged as reliable preclinical models to develop effective treatments in translational cancer research. Howe
Externí odkaz:
https://doaj.org/article/38683de5b53440cfb62abbde76cdcc3d
Autor:
Ismail M. Meraz, Mourad Majidi, RuPing Shao, Feng Meng, Min Jin Ha, Elizabeth Shpall, Jack A. Roth
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-13 (2022)
Meraz et al. explore the antitumor efficacy of TUSC2 tumor suppressor genetherapy via nanovisicles in combination with carboplatin and pembrolizumab against KRAS-LKB1 mutant NSCLC in humanized mouse model. They demonstrate a robust response and perfo
Externí odkaz:
https://doaj.org/article/022ff0137cd9475797f11973733dd01c
Autor:
Seyed Pairawan, Argun Akcakanat, Scott Kopetz, Coya Tapia, Xiaofeng Zheng, Huiqin Chen, Min Jin Ha, Yasmeen Rizvi, Vijaykumar Holla, Jing Wang, Kurt W. Evans, Ming Zhao, Naifa Busaidy, Bingliang Fang, Jack A. Roth, Ecaterina Ileana Dumbrava, Funda Meric-Bernstam
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-15 (2022)
Abstract Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-typ
Externí odkaz:
https://doaj.org/article/51b40b75a51c478a93d56c2bf88693c8
Autor:
Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina M. Primeau, Jeremy Hoog, Jacqueline L. Mudd, Dennis A. Dean, Rajesh Patidar, Li Chen, Matthew A. Wyczalkowski, Reyka G. Jayasinghe, Fernanda Martins Rodrigues, Nadezhda V. Terekhanova, Yize Li, Kian-Huat Lim, Andrea Wang-Gillam, Brian A. Van Tine, Cynthia X. Ma, Rebecca Aft, Katherine C. Fuh, Julie K. Schwarz, Jose P. Zevallos, Sidharth V. Puram, John F. Dipersio, The NCI PDXNet Consortium, Brandi Davis-Dusenbery, Matthew J. Ellis, Michael T. Lewis, Michael A. Davies, Meenhard Herlyn, Bingliang Fang, Jack A. Roth, Alana L. Welm, Bryan E. Welm, Funda Meric-Bernstam, Feng Chen, Ryan C. Fields, Shunqiang Li, Ramaswamy Govindan, James H. Doroshow, Jeffrey A. Moscow, Yvonne A. Evrard, Jeffrey H. Chuang, Benjamin J. Raphael, Li Ding
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-20 (2021)
Patient-derived xenograft models (PDX) have been extensively used to study the molecular and clinical features of cancers. Here the authors present a cohort of 536 PDX models from 25 cancers, as well as their genomic and evolutionary profiles and the
Externí odkaz:
https://doaj.org/article/e6286532f9bc487a87943a142621d7a3
Autor:
Ismail M. Meraz, Mourad Majidi, Bingliang Fang, Feng Meng, Lihui Gao, RuPing Shao, Renduo Song, Feng Li, Yonathan Lissanu, Huiqin Chen, Min Jin Ha, Qi Wang, Jing Wang, Elizabeth Shpall, Sung Yun Jung, Franziska Haderk, Philippe Gui, Jonathan Wesley Riess, Victor Olivas, Trever G. Bivona, Jack A. Roth
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/28e744ebeecd44eeb2ed3cadf1bc63a3
Autor:
Xingxiang Pu, Ran Zhang, Li Wang, Yungchang Chen, Yi Xu, Apar Pataer, Ismail M. Meraz, Xiaoshan Zhang, Shuhong Wu, Lin Wu, Dan Su, Weimin Mao, John V. Heymach, Jack A. Roth, Stephen G. Swisher, Bingliang Fang
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Background Because patient-derived xenografts (PDXs) are grown in immunodeficient mouse strains, PDXs are regarded as lacking an immune microenvironment. However, whether patients’ immune cells co-exist in PDXs remains uncharacterized. Met
Externí odkaz:
https://doaj.org/article/6894e6771c634171aa7604d1ac710e1d